Article
Nanoscience & Nanotechnology
Xingliang Dai, Yuxuan Shao, Xuefeng Tian, Xiaoyan Cao, Lei Ye, Peng Gao, Hongwei Cheng, Xianwen Wang
Summary: Cell fusion between GSCs and MSCs in 3D-bioprinted models promotes the progression of glioma by enhancing the malignant properties of the fused cells.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Review
Oncology
Rui Sun, Albert H. Kim
Summary: With the application of high throughput sequencing technologies at single-cell resolution, researchers have discovered immense cellular and tissue heterogeneity in the tumor microenvironment of glioblastoma. The interactions between malignant and immune cells generate an immunosuppressive microenvironment, while glioma stem cells play a critical role in tumor growth and therapeutic resistance.
CANCER AND METASTASIS REVIEWS
(2022)
Review
Cell Biology
Alireza Goodarzi, Mohsen Valikhani, Fatemeh Amiri, Armita Safari
Summary: Mesenchymal stem/stromal cells (MSCs) are characterized by unpredictable characteristics in their bone marrow niche, which makes them an issue in biology. MSCs are widely used in regenerative medicine due to their unique potentials for trans-differentiation, immunomodulation, and paracrine capacity. However, their pathogenic and pro-survival effects in tumors/cancers are undeniable.
CELL COMMUNICATION AND SIGNALING
(2022)
Review
Oncology
Frank Eckerdt, Leonidas C. Platanias
Summary: GSCs play a crucial role in the recurrence and resistance of glioblastoma by promoting tumor heterogeneity and modulating the tumor environment. They interact with cells of the immune system, aiding in immune evasion of malignant cells.
Review
Cell Biology
Qing Zhang, Jialin Wang, Junwen Zhang, Fusheng Liu
Summary: Mesenchymal stem cells (MSCs) play crucial roles in the tumor microenvironment (TME), contributing to tumor progression and therapeutic resistance. Glioma-resident MSCs (GR-MSCs) enhance the tumorigenicity of glioma stem cells (GSCs) through the IL-6/gp130/STAT3 pathway. Higher percentage of GR-MSCs in the TME leads to poor prognosis of glioma patients and their secretion of specific miRNA promotes tumor growth. Novel therapeutic strategies targeting GR-MSCs are urgently needed for GBM patients.
CELL BIOLOGY AND TOXICOLOGY
(2023)
Review
Cell Biology
Karina Biserova, Arvids Jakovlevs, Romans Uljanovs, Ilze Strumfa
Summary: Cancer stem cells, particularly in glioblastoma, play a crucial role in tumor resistance to treatment and recurrence. The regulatory mechanisms of glioma stem cells include tumor microenvironment, niche concept, metabolism, immunity, genetics, and epigenetics, which serve as potential targets for future treatments.Understanding the molecular markers and treatment resistance of GSCs in glioblastoma may lead to more effective therapeutic strategies in the future.
Article
Oncology
Haiyang Wang, Haoran Li, Qianqian Jiang, Xuchen Dong, Suwen Li, Shan Cheng, Jia Shi, Liang Liu, Zhiyuan Qian, Jun Dong
Summary: Recent studies have shown that Glioma Stem-like Cells (GSCs) can induce malignant transformation of fibroblasts (t-FBs) in the tumor microenvironment through the HOTAIRM1/miR-133b-3p/TGF beta axis. This finding could potentially provide a new target for treating gliomas.
FRONTIERS IN ONCOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Qiujun Qiu, Xinyi Ding, Jixiang Chen, Sunhui Chen, Jianxin Wang
Summary: Gliomas are aggressive and lethal tumors for which there are few treatment options. Nanobiotechnology offers promising strategies for early diagnosis, postoperative regrowth suppression, and microenvironment remodeling. It has the potential to address the challenges of managing recurrent glioma and accelerating drug development.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Oncology
Xiaobo Zheng, Chune Yu, Mingqing Xu
Summary: Cancer stem cells (CSCs) are a subset of cancer cells that drive tumor initiation, progression, and drug resistance. They exhibit plasticity, altering their phenotype and function, contributing to tumor relapse and metastasis. The tumor microenvironment (TME) plays a crucial role in regulating CSC plasticity, impacting cancer progression and drug resistance.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Marion Rabe, Lucie Fonteneau, Lisa Oliver, Alvaro Morales-Molina, Camille Jubelin, Javier Garcia-Castro, Dominique Heymann, Catherine Gratas, Francois M. Vallette
Summary: We have observed a drug-tolerant/persister state in a human glioblastoma (GBM) cell line after exposure to temozolomide. Single-cell analysis indicated the expression of four genes in different individual cells during the persister stage, suggesting a global answer. Thus, persisters might be a new therapeutically relevant target in GBM.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Imran Khan, Mohammad Hassan Baig, Sadaf Mahfooz, Moniba Rahim, Busra Karacam, Elif Burce Elbasan, Ilya Ulasov, Jae-June Dong, Mustafa Aziz Hatiboglu
Summary: Autophagy plays a crucial role in cellular energy consumption, survival, and defense mechanisms. Its impact on tumorigenesis and resistance mechanisms in glioblastoma remain ambiguous, highlighting the need for understanding the molecular mechanisms and designing improved treatment strategies. Autophagy also holds potential as a molecular target for therapeutic interventions in glioma stem cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Peng Xing, Shuo Wang, Yu Cao, Bo Liu, Feifei Zheng, Wei Guo, Junhao Huang, Zimo Zhao, Ziyi Yang, Xingda Lin, Liang Sang, Zhe Liu
Summary: This review summarizes the treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs. Although the molecular mechanisms of drug resistance in adenocarcinoma vary from one organ to another, there are universal targets that could potentially reverse drug resistance.
DRUG RESISTANCE UPDATES
(2023)
Article
Engineering, Biomedical
Minjun Xu, Yunlong Cheng, Ran Meng, Peng Yang, Jian Chen, Zhen Qiao, Jing Wu, Kang Qian, Yixian Li, Pengzhen Wang, Lingling Zhou, Tianying Wang, Dongyu Sheng, Qizhi Zhang
Summary: A novel microglia-targeted nano-immuno-synergist (DPAM@OA) carrying OA is devised to bolster microglia's immune function and incorporate DPPA-1 peptide to block PD-L1, effectively impeding the progression and recurrence of malignant glioma. This research highlights the promising therapeutic potential of well-designed nanocarriers in combining microglia repair with specific immunotherapy for brain tumors.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Cell & Tissue Engineering
Bing-zhou Xue, Wei Xiang, Qing Zhang, Hao-fei Wang, Yu-jie Zhou, Han Tian, Ahmed Abdelmaksou, Jian Xue, Min-xuan Sun, Dong-ye Yi, Nan-xiang Xiong, Xiao-bing Jiang, Hong-yang Zhao, Peng Fu
Summary: The study found that CD90(low) gaMSCs increased FOXS1 expression in glioma cells by secreting IL-6, leading to the activation of epithelial-mesenchymal transition and resistance to TMZ in these cells. These results reveal a new role of gaMSCs in promoting chemotherapy resistance.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Medicine, Research & Experimental
Nathaniel H. Boyd, Anh Nhat Tran, Joshua D. Bernstock, Tina Etminan, Amber B. Jones, G. Yancey Gillespie, Gregory K. Friedman, Anita B. Hjelmeland
Summary: Tumor microenvironments result from cellular alterations in cancer that promote unrestricted growth and angiogenesis, with hypoxia and acidic stress known to modulate therapeutic resistance. Understanding the interplay between tumor microenvironments and glioma stem cells is crucial for developing better treatment options for glioblastoma.